{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.0","upperLimit":"91.1","value":"84.3"}]}],"title":"Stable MMR for 48 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.7","upperLimit":"86.6","value":"78.7"}]}],"title":"Stable MMR for 96 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.8","upperLimit":"78.0","value":"68.5"}]}],"title":"Stable MMR for 144 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.7","upperLimit":"70.9","value":"60.7"}]}],"title":"Stable MMR for 192 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.6","upperLimit":"59.2","value":"48.3"}]}],"title":"Stable MMR for 240 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.3","upperLimit":"53.6","value":"42.7"}]}],"title":"Stable MMR for 288 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.1","upperLimit":"49.1","value":"38.2"}]}],"title":"Stable MMR for 336 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.0","upperLimit":"45.7","value":"34.8"}]}],"title":"Stable MMR for 384 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.0","upperLimit":"41.0","value":"30.3"}]}],"title":"Stable MMR for 432 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"}],"units":"Participants"}],"description":"The percentage of patients who were in stable MMR after achieving a response in the NTRI phase at multiple timepoints was calculated by dividing the number of participants achieving MMR any time during the NTRI phase and having the same response at those timepoints after the first achievement of MMR, irrespective of whether there was loss of MMR in between, by the number of patients who achieved MMR at any time during the NTRI phase.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who experienced loss of major molecular response during the treatment-free remission (TFR) phase entered the nilotinib treatment re-initiation (NTRI) phase. During this phase, nilotinib treatment was re-initiated at a dose of 300 mg twice daily.","id":"OG000","title":"NTRI Phase"}],"paramType":"NUMBER","populationDescription":"The nilotinib treatment re-initiation (NTRI) safety set included all participants who achieved MMR at least once in nilotinib re-initiation phase","reportingStatus":"POSTED","timeFrame":"Weeks 48, 96, 144, 192, 240, 288, 336, 384, and 432 after first achievement of MMR during the nilotinib re-initiation phase","title":"Percentage of Participants With Stable Major Molecular Response (MMR) at Multiple Time Points After First Achievement of MMR During Nilotinib Re-Initiation","type":"SECONDARY","unitOfMeasure":"percentage of participants"}